N-Ethyl-benzisoxazolium | 45894-32-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 英文名称: N-Ethyl-benzisoxazolium
• 英文别名: 2-Ethyl-1,2-benzoxazol-2-ium
• CAS: 45894-32-4
• 化学式: C₉H₁₀NO
• 分子量: 148.184
• InChiKey: ODXCMWLJDMOSSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  17
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20030134849A1

  公开（公告）日：2003-07-17

  A compound of formula (I) in which R 1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R 2 is amidated carboxy, R 3 is hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor &agr; (TNF &agr;).

  式(I)的化合物，其中R1是卤素、低碳氧基、可选取代芳基、可选取代芳氧基、可选取代杂环基或可选取代低炔基，R2是酰胺化羧基，R3是氢或酰基，Ar是芳基或杂环基，X是硫代、亚砜基或磺酰基，Y和Z是各自的低碳链基，m和n分别是0到2的整数，以及其盐，用作基质金属蛋白酶（MMP）抑制剂或肿瘤坏死因子α（TNFα）的产生。
• [EN] THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DERIVES DE L'ACIDE THIAZEPINYLHYDROXAMIQUE EN TANT QU'INHIBITEURS DES METALLOPROTEINASES MATRICIELLES
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2001060808A1

  公开（公告）日：2001-08-23

  A compound of formula (I) in which R1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R2 is amidated carboxy, R3 is hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor α (TNF α).

  化合物的化学式为（I），其中R1为卤素，较低的烷氧基，可选取代芳基，可选取代芳氧基，可选取代杂环基或可选取代较低的炔基，R2为酰胺化的羧基，R3为氢或酰基，Ar为芳基或杂环基，X为硫代基，亚砜基或磺酰基，Y和Z均为较低的烷基，m和n均为0到2的整数，以及其盐，用作基质金属蛋白酶（MMP）或肿瘤坏死因子α（TNFα）的抑制剂。
• Lower cycloalkyl substituted-benzene derivatives, the preparation thereof and their pharmaceutical compositions
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0000644A2

  公开（公告）日：1979-02-07

  Lower cycloalkyl substituted-benzene derivatives, the preparation thereof and their pharmaceutical compositions. Lower cycloalkyl substituted-benzene derivatives of the formula:- wherein R' is lower cycloalkyl, R2 is carboxy, esterified carboxy, hydroxymethyl, lower alkoxymethyl or acyloxymethyl, R3 is lower alkanoyl or lower alkyl substituted with hydroxy, amino, lower alkylamino, di(lower)alkylamino, acylamino, lower alkoxy, acyl or acyloxy, in which the lower alkyl moieties of the di(lower)alkyl amino radical may be joined together to form a heterocyclic ring containing the nitrogen atom and the carbonyl function of the acyl radical, which is a substituent on the lower alkyl radical, may be protected, X is hydrogen or halogen, and Y is a valency bond or lower alkylene; and pharmaceutically acceptable salts thereof; pharmaceutical composition comprising the same; and methods for treatment of inflammation by administering the same to mammals.

  下环烷基取代苯衍生物、其制备方法及其药物组合物。 式中的低级环烷基取代苯衍生物：- 低级环烷基取代苯衍生物 其中 R' 是低级环烷基、 R2 是羧基、酯化羧基、羟甲基、低级烷氧基甲基或酰氧基甲基、 R3是低级烷酰基或被羟基、氨基、低级烷基氨基、二（低级）烷基氨基、酰氨基、低级烷氧基、酰基或酰氧基取代的低级烷基，其中二（低级）烷基氨基的低级烷基可连接在一起形成含氮原子的杂环，酰基的羰基功能（低级烷基上的取代基）可被保护、 X 是氢或卤素，以及 Y 是价键或低级亚烷基； 及其药学上可接受的盐类； 包含上述物质的药物组合物；以及通过对哺乳动物施用上述物质治疗炎症的方法。
• Cephem compounds, processes for their preparation and pharmaceutical compositions containing them
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0007633A2

  公开（公告）日：1980-02-06

  A compound of the formula: wherein R1 is amino or protected amino, R2 is lower alkyl substituted with a substituent selected from the groups consisting of cyano, carbamoyl, hydroxy, protected hydroxy. amino. protected amino, lower alkoxy, lower alkylthio, lower alkenylthio, aryl which may have one or more suitable substituent(s). and heterocyclic group which may have one or more suitable substituent(s), R3 is carboxy or functionally modified carboxy, and R4 is hydrogen or halogen and its pharmaceutically acceptable salt and pharmaceutically acceptable bioprecursor thereof and process for their preparation. The invention also relates to a pharmaceutical composition comprising. as an effective ingredient, the above com. pound in association with a pharmaceutically acceptable, substantially nontoxic carrier or excipient. and to a method for treating an infectious disease caused by pathogenes, which comprises administering the above compound to infected human being or animals.

  式中的化合物： 其中 R1 是氨基或保护氨基、 R2是被选自以下组别的取代基取代的低级烷基：氰基、氨基甲酰基、羟基、受保护羟基、氨基、受保护氨基、低级烷氧基、低级烷硫基、低级烯硫基、可具有一个或多个合适取代基的芳基和可具有一个或多个合适取代基的杂环基、 R3 是羧基或官能修饰的羧基，以及 R4 是氢或卤素 及其药学上可接受的盐和药学上可接受的生物前体及其制备工艺。 本发明还涉及一种药物组合物，其有效成分包括与药学上可接受的、基本上无毒的载体或赋形剂一起使用的上述化合物；本发明还涉及一种治疗由病原体引起的传染病的方法，该方法包括将上述化合物施用于受感染的人或动物。
• 3,7-Disubstituted-2- or -3-cephem-4-carboxylic acid compounds, pharmaceutical compositions containing them and processes for the preparation thereof
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0010313A1

  公开（公告）日：1980-04-30

  New 3,7-disubstituted-2 or 3-cephem-4-carboxylic acid compounds of the formula: wherein R1 is amino or a substituted amino group; R2 is carboxy or a protected carboxy group; the group of the formula: is di(lower)alkylamino (lower)alkylamino, a N-containing heterocyclic (lower)alkylamino group which may have suitable substituent(s), a heterocyclic group containing 2 to 4 nitrogen atoms which may have suitable substituent(s) or hydroxypiperidino; and X is -S- or e.g. 7-[2-methoxyimino-2- (2-aminothiazol-4-yl) acetamido] -3-(4-methyl-1-piperazinyl) carbonyloxymethyl-3-cephem -4-carboxylic acid (syn isomer); pharmaceutically acceptablesalts thereof; and processes for their preparation. The invention also relates to pharmaceutical compositions comprising, as an effective ingredient, the above compounds in association with a pharmaceutically acceptable; substantially nontoxic carrier or excipient; and to a process for their preparation.

  式中的新的 3，7-二取代-2 或 3-头孢-4-羧酸化合物： 其中 R1 是氨基或取代的氨基 R2 是羧基或受保护的羧基； 式中的基团 是二(低级)烷基氨基(低级)烷基氨基、可有适当取代基的含 N 杂环(低级)烷基氨基基团、可有适当取代基的含 2 至 4 个氮原子的杂环基团或羟基哌啶基； X 是-S-或 例如，7-[2-甲氧基亚氨基-2-(2-氨基噻唑-4-基)乙酰氨基]-3-(4-甲基-1-哌嗪基)羰氧甲基-3-头孢-4-羧酸(同分异构体)；其药学上可接受的盐类；及其制备工艺。本发明还涉及由上述化合物作为有效成分与药学上可接受的、基本上无毒的载体或赋形剂结合而成的药物组合物，以及其制备工艺。